Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration

A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

(2017) S. I. Sherman et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers

(2014) Robert Shumaker et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2013) S. I. Shibata et al.   CLINICAL CANCER RESEARCH

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

(2012) D S Boss et al.   BRITISH JOURNAL OF CANCER

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects

(2012) Richat Abbas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Development and validation of LC–MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices

(2012) A.C. Dubbelman et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

(2011) Jiri Horak et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

(2011) K. Yamada et al.   CLINICAL CANCER RESEARCH

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

(2010) Carlo L. Bello et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study

(2010) Ophelia Q.P. Yin et al.   CLINICAL THERAPEUTICS

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

(2010) Michael A. Tortorici et al.   INVESTIGATIONAL NEW DRUGS

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

(2010) Dennis A. Smith et al.   NATURE REVIEWS DRUG DISCOVERY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

(2008) N Widmer et al.   BRITISH JOURNAL OF CANCER

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

(2008) J. Matsui et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

(2008) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY